Mar 16, 2022 / 05:50PM GMT
Ami Fadia - Needham & Company, LLC, Research Division - Research Analyst
Good afternoon, everyone. Welcome to the next session with Neurocrine Bioscience. Kyle, thank you so much for taking out the time to join today.
For those who are not very familiar with the company and with Kyle, Kyle is the Chief Business Development and Strategy Officer at Neurocrine. He's been with the company since 2011 and has been responsible for many of the business development collaborations that the company has and would love to spend the session that we have with Kyle to go over some of the many pipeline initiatives that the company is undertaking. But perhaps before we start, if I could ask Kyle to just give us some opening remarks, and we'll jump right into questions. And the audience can send me questions via the chat as well.
Kyle W. Gano - Neurocrine Biosciences, Inc. - Chief Business Development and Strategy Officer
Great. Thanks, Ami, and welcome to everyone here for the conference. It's a great lineup today. I'm just going over the agenda. It looks like a full
Neurocrine Biosciences Inc at Needham Neuroscience Forum (Virtual) Transcript
Mar 16, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers